BLS Pharmaceuticals Limited (ASX:BLS)
1.180
-0.025 (-2.07%)
Sep 22, 2026, 4:10 PM AEST
BLS Pharmaceuticals Revenue
In the fiscal year ending June 30, 2026, BLS Pharmaceuticals had annual revenue of 73.91M AUD with 152.42% growth. BLS Pharmaceuticals had revenue of 42.76M in the half year ending June 30, 2026, with 797.99% growth.
Revenue
73.91M
Revenue Growth
+152.42%
P/S Ratio
3.75
Revenue / Employee
n/a
Employees
n/a
Market Cap
277.52M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 73.91M | 44.63M | 152.42% |
| Jun 30, 2025 | 29.28M | 19.64M | 203.66% |
| Jun 30, 2024 | 9.64M | 4.34M | 81.98% |
| Jun 30, 2023 | 5.30M | 4.84M | 1,042.88% |
| Jun 30, 2022 | 463.64K | -1.74M | -78.97% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 94.02M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
| Orthocell | 11.41M |
| Recce Pharmaceuticals | 9.47M |
| Dimerix | 6.35M |
| Tetratherix | 3.86M |
| Racura Oncology | 2.81M |